
FDA Approves Pfizer’s HYMPAVZI™ for Hemophilia A and B Treatment
Pfizer Inc. (NYSE: PFE) has announced that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis. This treatment is designed to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients aged…











